Abstract: AIM: To evaluate the efficacy of recombinant coagulation factor Ⅶa (rFⅦa) for intraoperative bleeding management in Stanford type A aortic dissection.METHODS: 12 cases using rFⅦa in Stanford type A aortic dissection surgery as the experimental group, the remaining 20 cases without using rFⅦa was as the control group. The parameters of time of surgical hemostasis, the drainage volume in 24 h after operation, requirement of plasma and red blood cells in 24 h after operation were compared.RESULTS: In rFⅦa group, the significant reductions were observed in time of surgical hemostasis [(166±33) min vs (206±48) min, P＜0.05], the drainage volume in 24 h after operation [(666±195) mL vs (824±210) mL, P＜0.05] and the requirement of plasma in 24 h after operation [(525±157) mL vs (696±211) mL, P＜0.05], but the requirement of red blood cells in 24 h after operation was not significantly different between the two groups [(3.2±1.3) U vs (3.9±1.9) U, P＞0.05].CONCLUSION: The use of rFⅦa in Stanford type A aortic dissection surgery has a good hemostatic effect that can shorten the operation time, reduce the drainage volume, and save blood products.

Key words: Recombinant coagulation factor Ⅶa (rFⅦa), Aortic dissection, Hemostasis